Q4 2023 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2024-02-14 · accession 0000905148-24-000724
$667.2M
Reported value
7
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75525N107 | — | RAYZEBIO INC | $320.7M | 48.1% | 5,158,162 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $144.4M | 21.6% | 9,699,925 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $138.0M | 20.7% | 4,919,504 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $33.4M | 5.01% | 1,035,396 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $28.7M | 4.31% | 3,852,470 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $1.6M | 0.23% | 2,914,255 | Common | SOLE |
| 45258K109 | — | IMPEL PHARMACEUTICALS INC | $340,834 | 0.05% | 2,759,791 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.